Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Carlos M. Villalón
 -- 340 2023-07-12 09:55:54 |
2 As suggested, I have included full list of principal publications/works in JCR Journals, etc.
Carlos M. Villalón
 + 9554 word(s) 9954 2023-07-15 09:58:05 | |
3 format correct
Catherine Yang
 -1 word(s) 9954 2023-07-17 03:47:41 | |
4 format correct
Catherine Yang
 Meta information modification 9953 2023-07-17 03:49:45 | |
5 As suggested, I have included full list of principal publications/works in JCR Journals, etc.
Carlos M. Villalón
 Meta information modification 9953 2023-07-18 01:23:24 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Villalón, C.M. Carlos M. Villalón. Encyclopedia. Available online: https://encyclopedia.pub/entry/46683 (accessed on 17 November 2024).
Villalón CM. Carlos M. Villalón. Encyclopedia. Available at: https://encyclopedia.pub/entry/46683. Accessed November 17, 2024.
Villalón, Carlos M.. "Carlos M. Villalón" Encyclopedia, https://encyclopedia.pub/entry/46683 (accessed November 17, 2024).
Villalón, C.M. (2023, July 12). Carlos M. Villalón. In Encyclopedia. https://encyclopedia.pub/entry/46683
Villalón, Carlos M.. "Carlos M. Villalón." Encyclopedia. Web. 12 July, 2023.
Carlos M. Villalón
Edit
Curriculum Prof Villalon

1. Brief Introduction

Carlos M. Villalón was born in Mexico City on November 2, 1959. He completed his studies in Chemistry & Pharmacy (Pharmacist) in 1983 at the National School of Biological Sciences (IPN), and his postgraduate studies at the Department of Pharmacology and Toxicology of Cinvestav (M.Sc. in 1986 and Ph.D. in 1988). Between 1988 and 1991 he did a postdoctoral stay at the Erasmus Universiteit Rotterdam in the Netherlands. In 1991, he joined the Cinvestav Department of Pharmacology and Toxicology as a Senior Researcher.

2. Story about Notable Contributions and Implications for Sciences

His lines of research basically deal with: (1) The pharmacological identification/characterization of receptors for biogenic monoamines (including serotonin, catecholamines and histamine), calcitonin gene-related peptide (CGRP) and cannabinoids, as well as their role in cardiovascular regulation in several species of mammals; and (2) Research on the mechanisms of action of antimigraine agents and their cardiovascular side effects. These lines of research, as a whole, have generated (until 2022) more than 225 indexed (JCR) papers. According to Scopus citation analysis (until December 2022), these papers have generated 5,450 citations, classified as: 3,500 type A citations, H index: 32. Additionally, he has supervised 25 M.Sc. theses and 16 Ph.D. theses.

He has numerous national and international distinctions/awards. To mention just a few: Member of the National System of Investigators (S.N.I.) since 1992, with Emeritus level since January 2022 (File 13369). Member of the Ruling/Promotion Commission of the S.N.I. (2000-2002) and the Review Commission of the S.N.I. (2013) in Area III (Medicine and Health Sciences). Member of the Cinvestav-IPN Ruling/Promotion Commission since 1995. Research Award 1998 in Natural Sciences, awarded by the MEXICAN ACADEMY OF SCIENCES. Invited as a member of the editorial committee of 5 indexed (JCR) journals located in Q1 of the JCR. Chief Organizer of two international congresses. Trainer of active and independent researchers, who in turn have graduated their own postgraduate students. In 2009 he was promoted to the highest Cinvestav Researcher Category (3F) and in 2022 to Cinvestav Emeritus Researcher category. Currently, Cinvestav-IPN has a total of 615 researchers throughout the country and, of these, only 33 researchers hold the 3F category and 21 the Cinvestav Emeritus Researcher category.

3. A Full List of Principal Publications/ Works in JCR Journals, Chapters Published in International Books by Prestigious Publishers, etc.

3.1. Principal Publications/ Works in JCR Journals

  • Mourelle, M., Villalón, C. & Amezcua, J.L. Protective effect of colchicine on acute liver damage induced by carbon tetrachloride. Hepatol., 6, 337‑342, 1988. (2016 JCR Impact Factor: 11.336).
  •  
  • Bom, A., Villalón, C.M., Verdouw, P. & Saxena, P.R., The 5‑HT1‑like receptor mediating reduction of porcine carotid arteriovenous shunting by RU 24969 is unrelated to either 5‑HT1A or 5‑HT1B Eur. J. Pharmacol., 171, 87‑96, 1989. (2016 JCR Impact Factor: 2.896).

  • Villalón, C.M., Den Boer, M.O., Heiligers, J.P.C. & Saxena, P.R. Mediation of 5‑hydroxytryptamine‑induced tachycardia in the pig by the putative 5‑HT4 Brit. J. Pharmacol., 100, 665‑667, 1990. (2016 JCR Impact Factor: 5.491).

  • Villalón, C.M., Bom, A.H., Heiligers, J., den Boer, M.O. & Saxena, P.R. Constriction of porcine arteriovenous anastomoses by indorenate is unrelated to 5‑HT1A, 5‑HT1B, 5‑HT1C or 5‑HT1D receptor subtype. Eur. J. Pharmacol., 190, 167‑176, 1990. (2016 JCR Impact Factor: 2.896).
  •  
  • Saxena, P.R. & Villalón, C.M. Brain 5‑HT1A receptor agonism: A novel mechanism for antihypertensive action. Trends Pharmacol. Sci., 11, 95‑96, 1990. (2016 JCR Impact Factor: 12.797).
  • Saxena, P.R. & Villalón, C.M. Cardiovascular effects of serotonin agonists and antagonists. Cardiovasc. Pharmacol., 15 (Suppl. 7), S17‑S34, 1990. (2016 JCR Impact Factor: 2.462).

  • Villalón, C.M., Den Boer, M.O., Heiligers, J.P.C. & Saxena, P.R. Further characterization, using tryptamine and benzamide derivatives, of the 5‑HT4 receptor mediating tachycardia in the pig. Brit. J.Pharmacol., 102, 107‑112, 1991. (2016 JCR Impact Factor: 5.491).
  • Den Boer, M.O., Villalón, C.M., Heiligers, J.P.C., Humphrey, P.P.A. & Saxena, P.R. Role of 5‑HT1‑like receptors in the reduction of porcinecranial arteriovenous anastomotic shunting bysumatriptan. Brit. J. Pharmacol., 102, 323‑330, 1991. (2016 JCR Impact Factor: 5.491).
  • Saxena, P.R. & Villalón, C.M. 5‑Hydroxytryptamine, a chameleon in the heart. Trends  Pharmacol. Sci., 12, 223‑227, 1991. (2016 JCR Impact Factor: 12.797).

  • Villalón, C.M., Bom, A.H., Den Boer, M.O. Heiligers, J.P.C. & Saxena, P.R. Effects of S9977, a potential antimigraine drug, and dihydroergotamine on carotid blood flow fractionation in the pig. Pharmacol. Res., 25, 125‑137, 1992. (2016 JCR Impact Factor: 4.816).
  • Dhasmana, K.M., Villalón, C.M., Zhu, Y.N., Tadipatri, S. & Saxena, P.R. Role of 5‑HT1‑like receptors in the increase in intragastric pressure induced by 5‑hydroxytryptamine in the rat. Eur. J. Pharmacol., 213, 293‑299, 1992. (2016 JCR Impact Factor: 2.896).
  • Den Boer, M.O., Villalón, C.M. & Saxena, P.R. 5‑HT1‑like receptor‑mediated changes in porcine carotid haemodynamics: are 5‑HT1D receptors involved? Naunyn‑Schmiedeberg’s Arch. Pharmacol., 345, 509‑515, 1992. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. ).
  • Terrón, J.A., Ranzans, V., Ibarra, M., Hong, E. & Villalón, C.M. Alpha1-adrenoceptor blocking properties of spiroxatrine in rat aorta. Life Sciences, 51,PL1‑PL6, 1992. (2016 JCR Impact Factor: 2.685).
  • Saxena, P.R., Heiligers, J.P.C., Villalón, C.M. & Ferrari, D. Effects of tertatolol, a ß‑adrenoceptor antagonist with agonist affinity at 5‑HT1A receptors, in an animal model of migraine: comparison with propranolol and pindolol. Eur. J. Pharmacol., 220, 79‑86,1992. (2016 JCR Impact Factor: 2.896).
  • Saxena, P.R., Villalón, C.M., Dhasmana, M. & Verdouw, P.D. 5‑HT‑induced increase in left ventricular dP/dtmax does not suggestthe presence of ventricular 5‑HT4 receptors in the pig. Naunyn‑Schmiedeberg’Pharmacol., 346, 629‑636, 1992. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. Pharmacol.).
  • Dhasmana, K., Villalón, C.M., Zhu, Y. & Parmar, S.S. The role of dopamine (D2), a- and ß‑adrenergic receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine‑related drugs in the rat. Pharmacol. Res., 27, 335‑347, 1993. (2016 JCR Impact Factor: 4.816).

  • Villalón, C.M., Terrón, J.A. & Hong, E. Role of 5‑HT1‑like receptors in the increase in external carotid blood flow induced by 5‑hydroxytrytamine in the dog. Eur. J. Pharmacol., 240, 9‑20, 1993. (2016 JCR Impact Factor: 2.896).

  • Villalón, C.M., Terrón, J.A. & Hong, E. Further characterization of the 5‑hydroxytryptamine1‑like receptors mediating the increase in external carotid blood flow in the dog. Drug Develop. Res., 29, 271‑281, 1993. (2016 JCR Impact Factor: 1.902).
  • López‑Muñoz, F.J., Castañeda‑Hernández, G., Villalón, C.M., Terrón, J.A. & Salazar, L.A. Analgesic effects of combinations containing opioid drugs with either aspirine or acetaminophen in the rat. Drug Develop. Res., 29, 299‑304, 1993. (2016 JCR Impact Factor: 1.902).

  • Villalón, C.M., Hong, E. & Terrón, J.A. Influence of sympathetic tone on the reactivity to indorenate in the external carotid bed of the dog. Med.Res., 24, 147‑154, 1993. (2016 JCR Impact Factor: 2.219).
  • Dhasmana, K.M., Zhu, Y.N., Cruz, S.L. & Villalón, C.M. Gastrointestinal effects of 5‑hydroxytryptamine and related drugs. Life Sci., 53, 1651‑1661, 1993. (2016 JCR Impact Factor: 2.685).
  • Terrón, J.A., Hong, E. & Villalón, C.M. Pharmacological screening of some quinoline derivatives in canine vascular smooth muscle. Arch. Med. Res., 25, 435‑440, 1994. (2016 JCR Impact Factor: 2.219).
  • Terrón, J.A., López‑Muñoz, F.J., Hong, E. & Villalón, C.M. 2‑(2‑Aminoethyl)‑quinoline (D‑1997): a novel agonist at 5‑HT1‑like receptors in the canine basilar artery. Arch. Int. Pharmacodyn. Ther., 327, 56‑68, 1994. (Estuvo en circulación de 1899 a 1996. En 1997 cambió de nombre a Fundamental & Clinical Pharmacology). (2016 JCR Impact Factor: 2.156).

  • Villalón, C. M. & Terrón, J.A. The 5‑HT1‑like receptor mediating the increase in canine external carotid blood flow: close resemblance to the 5‑HT1D Brit. J. Pharmacol., 113, 13‑20, 1994. (2016 JCR Impact Factor: 5.491).
  • Terrón, J.A., Hong, E., López‑Muñoz, F.J. & Villalón, C.M. Inhibition of serotonin‑induced increase in canine external carotid blood flow by drugs that decrease the sympathetic outflow. J. Auton. Pharmacol., 14, 165‑175, 1994. 
  • López‑Muñoz, F., Villalón, C.M., Terrón, J. & Salazar, L.A. Analgesic interactions produced by dipyrone and either morphine or D‑propoxyphene in the pain‑induced functional impairment model in the rat. Drug Develop. Res., 32, 50‑57, 1994. (2016 JCR Impact Factor: 1.902).
  • Castillo, C., Ibarra, M., Terrón, J.A., Villalón, C.M. & Hong, E. Direct effects of indorenate and 8‑OH‑DPAT on the blood pressure of pithed rats. Drug Develop. Res., 33, 20‑25, 1994. (2016 JCR Impact Factor: 1.902).

  • Villalón, C.M., Contreras, J., Ramírez‑San Juan, E., Castillo, C., Perusquía, M., López‑Muñoz, F.J. & Terrón, J.A. 5‑Hydroxytryptamine inhibits pressor responses to preganglionic sympathetic nerve stimulation in pithed rats. Life Sci., 57, 803‑812, 1995. (2016 JCR Impact Factor: 2.685).
  • López‑Muñoz, F.J., Villalón, C.M., Terrón, J.A. & Salazar, L.A. Doses of acetyl salicylic acid‑morphine which provided in combination either maximal levels of analgesia or the highest potentiation effect in rat. Drug. Develop. Res., 35, 94‑101, 1995. (2016 JCR Impact Factor: 1.902).
  • Villalón, C.M., Ramírez‑San Juan, E., Castillo, C., López‑Muñoz, F.J. & Terrón, J.A. Pharmacological profile of the receptors that mediate external carotid vasoconstriction by 5‑HT in vagosympathectomized dogs. Eur. J. Pharmacol., 116, 2778‑2784, 1995. (2016 JCR Impact Factor: 5.491).

  • Villalón, C.M., Terrón, J.A., Ramírez‑San Juan, E. & Saxena, P.R. 5‑Hydroxytryptamine: considerations about discovery, receptor classification and relevance to medical research. Arch. Med. Res., 26, 331‑344, 1995. (2016 JCR Impact Factor: 2.219).

  • Villalón, C.M., Contreras, J., Ramírez‑San Juan, E., Castillo, C., Perusquía, M. & Terrón, J.A. Characterization of prejunctional 5‑HT receptors mediating inhibition of sympathetic vasopressor responses in the pithed rat. Brit. J. Pharmacol., 116, 3330‑3336, 1995. (2016 JCR Impact Factor: 5.491).
  • Perusquía, M. & Villalón, C.M. The relaxant effect of sex steroids in rat myometrium is independent of the gamma‑amino butyric acid system. Life Sciences, 58, 913‑926, 1996. (2016 JCR Impact Factor: 2.685).
  • Terrón, J.A., Ramírez‑San Juan, E., Hong, E. & Villalón, C.M., Role of a1-adrenoceptors in the reduction of external carotid blood flow induced by buspirone and ipsapirone in the dog. , Life Sciences, 58, 63‑73, 1996. (2016 JCR Impact Factor: 2.685).
  • Perusquía, M., Hernández, R., Morales, M.A., Campos, M.G. & Villalón, C.M. Role of endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. Gen. Pharmacol., 27, 181‑185, 1996. Ha estado indexada, y en 2002 cambió de nombre a Vascular Pharmacology. (2016 JCR Impact Factor: 2.500).
  • Terrón, J.A., Castillo, C., Sánchez, A., Ramírez‑San Juan, E. & Villalón, C.M. Influence of 5‑HT on the pressor responses induced by norepinephrine and electrical sympathetic stimulation in the pithed rat. Arch. Med.Res., 27, 291‑297, 1996. (2016 JCR Impact Factor: 2.219).

  • Villalón, C.M., Sánchez‑López, A. & Centurión, D. Operational characteristics of the 5‑HT1‑like receptors mediating external carotid vasoconstriction in vagosympathectomized dogs: close resemblance to the 5‑HT1D receptor subtype. Naunyn‑Schmiedeberg’s Arch. Pharmacol., 354, 550‑556, 1996. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. ).
  • De Vries, P., Heiligers, J.P.C., Villalón, C.M. & Saxena, P.R., Blockade of porcine carotid vascular responses to sumatriptan by GR127935, a selective 5‑HT1D receptor antagonist. Brit. J. Pharmacol., 118, 85‑92, 1996. (2016 JCR Impact Factor: 5.491).

  • Villalón, C.M., Centurión, D., Luján‑Estrada, M., Terrón, J.A. & Sánchez‑López, A. Mediation of 5‑HT‑induced external carotid vasodilatation in GR127935‑pretreated vagosympathectomized dogs by the putative 5‑HT7 Brit. J. Pharmacol., 120, 1319‑1327, 1997. (2016 JCR Impact Factor: 5.491).
  • De Vries, P., Apaydin, S., Villalón, C.M., Heiligers, J.P.C. & Saxena, P.R. Interactions of GR127935, a 5‑HT1B/D receptor ligand, with functional 5‑HT receptors. Naunyn‑Schmiedeberg’s Arch. Pharmacol., 355, 423‑430, 1997. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. ).
  • Villalón, C.M., Heiligers, J.P.C., Centurión, D., De Vries, P. & Saxena, P.R. Characterization of putative 5‑HT7 receptors mediating tachycardia in the cat. Brit. J. Pharmacol., 121, 1187‑1195, 1997. (2016 JCR Impact Factor: 5.491).
  • De Vries, P., Villalón, C.M., Heiligers, J.P.C. & Saxena, P.R. Nature of 5‑HT1‑like receptors mediating depressor responses in vagosympathectomized rats; close resemblance to the cloned 5‑ht7 Naunyn‑Schmiedeberg’s Arch. Pharmacol., 356, 90‑99, 1997. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. Pharmacol.).
  • Perusquía, M., Hernández, R., Montaño, L.M. & Villalón, C.M. Inhibitory effect of sex steroids on guinea‑pig airway smooth muscle contractions. Biochem. Physiol., 118C, 5‑10, 1997. (2016 JCR Impact Factor: 2.546).
  • Castillo, E.F., Valencia, I., Bobadilla, R.M., Villalón, C.M. & Castillo, C. a‑Methylnoradrenaline‑induced contractions in rat aorta are mediated via a1D‑adrenoceptors. Fund. Clin. Pharmacol., 11, 339‑345, 1997. (2016 JCR Impact Factor: 2.156).

  • Villalón, C.M., De Vries, P. & Saxena, P.R. Serotonin receptors as cardiovascular targets. Today, 2, 294‑300, 1997. (2016 JCR Impact Factor: 5.625).
  • De Vries, P., Villalón, C.M., Heiligers, J.P.C. & Saxena, P.R. Characterization of 5‑HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5‑HT1B/1D and novel receptors. Brit. J. Pharmacol., 123, 1561‑1570, 1998. (2016 JCR Impact Factor: 5.491).

  • Villalón, C.M., Centurión, D., Rabelo, G., De Vries, P., Saxena, P.R. & Sánchez‑López, A. The 5‑HT1‑like receptors mediating inhibition of sympathetic vasopressor outflow in the pithed rat: operational correlation with the 5‑HT1A, 5‑HT1B and 5‑HT1D Brit. J. Pharmacol., 124, 1001‑1011, 1998. (2016 JCR Impact Factor: 5.491).
  • De Vries, P., Willems, E.W., Heiligers, J.P.C., Villalón, C.M., & Saxena, P.R. The antimigraine agent alniditan selectively constricts porcine carotid arteriovenous anastomoses via 5‑HT1B/1D Eur.J. Pharmacol., 351, 193‑201, 1998. (2016 JCR Impact Factor: 2.896).

  • Villalón, C.M., López‑Muñoz, F.J., Perusquía, M. & Terrón, J.A. External carotid effects of 2‑(2‑aminoethyl)‑quinoline (D‑1997) in vagosympathectomized dogs. Eur. J. Pharmacol., 356, 15‑23, 1998. (2016 JCR Impact Factor: 2.896).
  • Saxena, P.R., De Vries, P. & Villalón, C.M. 5‑HT1‑like receptors: a time to bid good‑bye. Trends Pharmacol. Sci., 19, 311‑316, 1998. (2016 JCR Impact Factor: 12.797).
  • De Vries, P., Sánchez‑López, A., Centurión, D., Heiligers, J.P.C., Saxena, P.R. & Villalón, C.M. The canine external carotid vasoconstrictor 5‑HT1 receptor: blockade by 5‑HT1B (SB224289), but not by 5‑HT1D (BRL15572) receptor antagonists. Eur. J. Pharmacol., 362, 69‑72, 1998. (2016 JCR Impact Factor: 2.896).

  • Villalón, C.M., De Vries, P., Rabelo, G., Centurión, D., Sánchez‑López, A. & Saxena, P.R. Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5‑HT1B/1D receptors and alpha2‑adrenoceptors Brit. J. Pharmacol., 126, 585‑594, 1999. (2016 JCR Impact Factor: 5.491).

  • Villalón, C.M., Centurión, D., Fernández, M.M., Morán, A. & Sánchez‑López, A. 5‑Hydroxytryptamine inhibits the tachycardia induced by selective preganglionic sympathetic stimulation in pithed rats. Life Sciences, 64, 1839-1847, 1999. (2016 JCR Impact Factor: 2.685).
  • Perusquía M. & Villalón, C.M. Possible role of calcium channels in the vasodilating effect of 5ß‑dihydrotestosterone in rat aorta. Eur. J. Pharmacol., 371, 169‑178, 1999. (2016 JCR Impact Factor: 2.896).
  • De Vries, P., Willems, E.W., Heiligers, J.P.C., Villalón, C.M. & Saxena, P.R. Investigation of the role of 5‑HT1B and 5‑HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses. Brit. J. Pharmacol., 127, 405-412, 1999. (2016 JCR Impact Factor: 5.491).
  • De Vries, P., De Visser, P.A., Heiligers, J.P.C., Villalón, C.M. & Saxena, P.R. Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats. Naunyn‑Schmiedeberg’s Arch. Pharmacol., 359, 331-338, 1999. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. ).
  • Willems, E.W., Trion, M., De Vries, P., Heiligers, J.P.C., Villalón, C.M. & Saxena, P.R. Pharmacological evidence that alpha1- and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Brit. J. Pharmacol., 127, 1263-1271, 1999. (2016 JCR Impact Factor: 5.491).
  • Castillo, C., Asbun, J., Escalante, B., Villalón, C.M., López, P. & Castillo, E. Thiopental inhibits nitric oxide production in rat aorta. Can J. Physiol. Pharmacol., 77, 958‑966, 1999. (2016 JCR Impact Factor: 1.704)
  • De Vries, P., Villalón, C.M. & Saxena, P.R. Pharmacology of triptans. Emerging Drugs, 4, 107‑125, 1999. (Estuvo indexada como tal y en 2001 cambió de nombre a Expert Opinion on Emerging Drugs; sigue indexada). (2016 JCR Impact Factor: 2.120).
  • De Vries, P., Villalón, C.M. & Saxena, P.R. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur. J. Pharmacol., 375, 61‑74, 1999. (2016 JCR Impact Factor: 2.896).

  • Villalón, C.M., Centurión, D., Sánchez-López, A., De Vries, P. & Saxena, P.R. 5‑HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs. Acta Pharmacol. Sin. (también denominada como Zhongguo Yao Li Xue Bao), 20, 1057-1067, 1999. (2016 JCR Impact Factor: 3.166).

  • Villalón, C.M., Centurión, D., Bravo, G., de Vries, P., Saxena, P.R. & Ortiz, M.I. Further pharmacological analysis of the orphan 5-HT receptors mediating feline vasodepressor responses: close resemblance to the 5‑HT7 Naunyn-Schmiedeberg’s Arch. Pharmacol., 361, 665‑671, 2000. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. Pharmacol.).
  • Centurión, D., Sánchez‑López, A., Ortiz, M.I., De Vries, P., Saxena, P.R. & Villalón,C.M. Mediation of 5-HT-induced internal carotid vasodilatation in GR127935- and ritanserin-pretreated dogs by 5-HT7 Naunyn‑Schmiedeberg’s Arch. Pharmacol., 362, 169-176, 2000. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. Pharmacol.).

  • Villalón, C.M., Sánchez‑López, A., Centurión, D. & Saxena, P.R. Unravelling the pharmacological profile of the canine external carotid vasodilator “5‑HT1‑like” receptors: coexistence of sympathoinhibitory 5‑HT1B receptors and postjunctional 5‑HT7 Naunyn‑Schmiedeberg’s Arch. Pharmacol., 363, 73-80, 2001. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. Pharmacol.).
  • Centurión, D., Ortiz, M.I., Sánchez‑López, A., De Vries, P., Saxena, P.R. & Villalón, C.M. Evidence for 5‑HT1B/1D and 5‑HT2A receptors mediating constriction of the canine internal carotid circulation. Brit. J. Pharmacol., 132, 983-990, 2001. (2016 JCR Impact Factor: 5.491).
  • Centurión, D., Sánchez‑López, A., De Vries, P., Saxena, P.R. & Villalón, C.M. The GR127935‑sensitive 5‑HT1 receptors mediating canine internal carotid vasoconstriction: resemblance to the 5‑HT1B, but not to the 5‑HT1D or 5‑ht1F receptor subtype. Brit. J. Pharmacol., 132, 991-998, 2001. (2016 JCR Impact Factor: 5.491).
  • Willems, E.W., Valdivia, L.F., Ramírez-San Juan, E., Saxena, P.R. & Villalón, C.M. Pharmacological identification of the major subtypes of adrenoceptors involved in the canine external carotid vasoconstrictor effects of adrenaline and noradrenaline. Life Sci., 69, 143‑153, 2001. (2016 JCR Impact Factor: 2.685).
  • Willems, E.W., Valdivia, L.F., Saxena, P.R. & Villalón, C.M. The role of several a1- and a2-adrenoceptor subtypes mediating vasoconstriction in the canine external carotid circulation. Brit. J. Pharmacol., 132, 1292‑1298, 2001. (2016 JCR Impact Factor: 5.491).
  • Willems, E.W., De Vries, P., Heiligers, J.P.C., Tom, B., Villalón, C.M., & Saxena, P.R. a1‑adrenoceptor subtypes mediating vasoconstriction in the carotid vascular bed of anaesthetised pigs; possible avenues for antimigraine drug development. Cephalalgia, 21, 110‑119, 2001. (2016 JCR Impact Factor: 6.052).
  • Willems, E.W., De Vries, P., Heiligers, J.P.C., Tom, B., Villalón, C.M., & Saxena, P.R. A‑61603‑induced vasoconstriction in the porcine carotid vasculature: possible involvement of a novel receptor. Eur. J. Pharmacol., 417, 195‑201, 2001. (2016 JCR Impact Factor: 2.896).
  • Willems, E.W., Valdivia, L.F., Saxena, P.R. & Villalón, C.M. Pharmacological profile of the mechanisms involved in the external carotid vascular effects of the antimigraine agent isometheptene in anaesthetised dogs. Naunyn‑Schmiedeberg’s Arch. Pharmacol., 364, 27‑32, 2001. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. ).
  • Centurión, D., Ortiz, M.I., Saxena, P.R. & Villalón, C.M. The atypical 5‑HT2 receptors mediating tachycardia in pithed rats: pharmacological correlation with the 5‑HT2A receptor subtype. Brit. J. Pharmacol., 135, 1531‑1539, 2002. (2016 JCR Impact Factor: 5.491).
  • Perusquía, M. & Villalón, C.M. The vasodepressor effect of androgens in pithed rats: potential role of calcium channels. Steroids, 67, 1027-1034, 2002. (2016 JCR Impact Factor: 2.513).
  • Willems, E., Valdivia, L.F., Villalón, C.M. & Saxena, P.R. a‑adrenoceptors and acute migraine therapy. Drug News Perspect., 15, 140-146, 2002. (2016 JCR Impact Factor: 3.132).
  • Willems, E.W., Valdivia, L.F., Villalón, C.M. & Saxena, P.R. Possible role of a‑adrenoceptor subtypes in acute migraine therapy. Cephalalgia, 23, 245-257, 2003. (2016 JCR Impact Factor: 6.052)

  • Villalón, C.M., Ramírez-San Juan, E., Sánchez-López, A., Bravo, G., Willems, E.W., Saxena, P.R. & Centurión, D. Pharmacological profile of the vascular responses to dopamine in the canine external carotid circulation. Pharmacol. & Toxicol., 92, 165‑172, 2003. (siempre ha estado indexada y en 2004 cambió de nombre a Basic & Clinical Pharmacology & Toxicology). (2016 JCR Impact Factor: 3.097).
  • Sánchez-López, A., Centurión, D., Vázquez, E., Arulmani, U., Saxena, P.R. & Villalón, C.M. Pharmacological profile of the 5‑HT‑induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5‑HT1 and putative 5‑ht5A/5B Brit. J. Pharmacol., 140, 725‑735, 2003. (2016 JCR Impact Factor: 5.491).
  • Villalón, C.M., Centurión, D., Valdivia, L.F., de Vries, P. & Saxena, P.R. Migraine: an updated review on pathophysiology, pharmacology, therapy and future trends. Curr. Vasc. Pharmacol., 1, 71‑84, 2003. (2016 JCR Impact Factor: 2.374).
  • Kapoor, K., Arulmani, U., Heiligers, J.P.C., Garrelds, I.M., Willems, E.W., Doods, H., Villalón, C.M. & Saxena, P.R. Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Brit. J. Pharmacol., 140, 329‑338, 2003. (2016 JCR Impact Factor: 5.491).
  • Kapoor, K., Arulmani, U., Heiligers, J.P.C., Willems, E.W., Doods, H., Villalón, C.M. & Saxena, P.R. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynarnic responses in the pig. Eur. J. Pharmacol., 475, 69‑77, 2003. (2016 JCR Impact Factor: 2.896).

  • Villalón, C.M., Centurión, D., Willems, E.W., Arulmani, U., Saxena, P.R. & Valdivia, L.F. 5‑HT1B receptors and a2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur. J. Pharmacol. 484, 287‑290, 2004. (2016 JCR Impact Factor: 2.896).
  • Sánchez-López, A., Centurión, D., Vázquez, E., Arulmani, U., Saxena, P.R. & Villalón, C.M. Further characterization of the 5‑HT1 receptors mediating cardiac sympatho‑inhibition in pithed rats: pharmacological correlation with the 5‑HT1B and 5‑HT1D Naunyn‑Schmiedeberg’s Arch. Pharmacol., 369, 220‑227, 2004. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. Pharmacol.).
  • Valdivia, L.F., Centurión, D., Perusquía, M., Arulmani, U., Saxena, P.R. & Villalón, C.M. Pharmacological analysis of the mechanisms involved in the tachycardic and vasopressor responses to the antimigraine agent, isometheptene, in pithed rats. Life Sci., 74, 3223-3234, 2004. (2016 JCR Impact Factor: 2.685).
  • Bravo, G., Guízar-Sahagún, G., Ibarra, A., Centurión, D. &Villalón, C.M. Cardiovascular alterations after spinal cord injury: an overview. Curr. Med. Chem. (Cardiovasc. Haematol. Ag.), 2, 133‑148, 2004. (2016 JCR Impact Factor: 3.455).
  • Arulmani, U., Schuijt, M.P., Heiligers, J.P.C., Willems, E.W., Villalón, C.M., & Saxena, P.R. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on a-CGRP‑induced regional haemodynamic changes in anaesthetised rats. Basic Clin. Pharmacol. & Toxicol., 94, 291-297, 2004. (2016 JCR Impact Factor: 3.097).
  • Valdivia, L.F., Centurión, D., Arulmani, U., Saxena, P.R. & Villalón, C.M. 5‑HT1B receptors, a2A/2C- and, to a lesser extent, a1‑adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomized dogs. Naunyn‑Schmiedeberg’s Arch. Pharmacol., 370, 46-53, 2004. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. ).
  • Arulmani, U., Heiligers, J.P.C., Garrelds, I.M., Sánchez‑López, A., Willems, E.W., Villalón, C.M. & Saxena, P.R. Effects of sumatriptan on capsaicin‑induced carotid haemodynamic changes and CGRP release in anaesthetised pigs. Cephalalgia, 24, 717‑727, 2004. (2016 JCR Impact Factor: 6.052).
  • Arulmani, U., MaassenVanDenBrink, A., Villalón, C.M. & Saxena, R. Calcitonin gene‑related peptide and its role in migraine pathophysiology. Eur. J. Pharmacol., 500, 315‑330, 2004. (2016 JCR Impact Factor: 2.896).
  • Centurión, D., Glusa, E., Sánchez-López, A., Valdivia, L.F., Saxena, P.R. &Villalón, C.M. 5-HT7, but not 5‑HT2B, receptors mediate hypotension in vagosympathectomized rats. Eur. J. Pharmacol., 502, 239‑242, 2004. (2016 JCR Impact Factor: 2.896).
  • Vázquez, E., Coronel, I., Bautista, R., Romo, E., Villalón, C.M., Avila-Casado, M.C., Soto, V. & Escalante, B. AngiotensinII‑dependent induction of AT2 receptor expression after renal ablation. J. Physiol. (Renal Physiol.), 288, F207-F213, 2005. (2016 JCR Impact Factor: 3.390).
  • Arulmani, U., Heiligers, J.P.C., Centurión, D.,Garrelds, I.M., Villalón, C.M. & Saxena, P.R. Lack of effect of the adenosine A1 receptor agonist, GR79236, on capsaicin-induced CGRP release in anaesthetised pigs. Cephalalgia, 25, 1082‑1090, 2005. (2016 JCR Impact Factor: 6.052).
  • Gupta, S., Mehrotra, S.,Villalón, C.M.,Garrelds, I.M., deVries, R., van Kats, J.P.,Sharma, H.S.,Saxena, P.R. & MaassenVanDenBrink, A. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur. J. Pharmacol., 530, 107‑116, 2006. (2016 JCR Impact Factor: 2.896).
  • Centurión, D., Sánchez-López, A., Gupta, S., Mehotra, S., MaassenVanDenBrink, A. & Villalón, C.M. Potential vascular alpha1‑adrenoceptor blocking properties of an array of 5‑HT receptor ligands in the rat. Eur. J. Pharmacol., 535, 234‑242, 2006. (2016 JCR Impact Factor: 2.896).
  • Arulmani, U., Gupta, S., MaassenVanDenBrink, A., Centurión, D., Villalón, C.M. & Saxena, P.R. Experimental migraine models and their relevance in migraine therapy. Cephalalgia, 26, 642‑659, 2006. (2016 JCR Impact Factor: 6.052)

  • Gupta, S., Mehrotra, S., Avezaat, C.J.J., Villalón, C.M.,Saxena, P.R. & MaassenVanDenBrink, A. Characterisation of CGRP receptors in the human isolated middle meningeal artery. Life Sci. 79, 265‑271, 2006. (2016 JCR Impact Factor: 2.685).
  • Jiménez-Mena, L.R., Gupta, S., Muñoz-Islas, E., Lozano‑Cuenca, J., Sánchez‑López, A., Centurión, D., Mehrotra, S., MaassenVanDenBrink, A. & Villalón, C.M. Clonidine inhibits the canine external carotid vasodilatation to capsaicin by alpha2A/2C-adrenoceptors. Eur. J. Pharmacol., 543, 68‑76, 2006. (2016 JCR Impact Factor: 2.896).
  • Muñoz-Islas, E., Gupta, S., Jiménez-Mena, L.R., Lozano‑Cuenca, J., Sánchez‑López, A., Centurión, D., Mehrotra, S., MaassenVanDenBrink, A. & Villalón, C.M. Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D Brit. J. Pharmacol., 149, 82-91, 2006. (2016 JCR Impact Factor: 5.491).
  • Mehrotra, S., Gupta, S., Garrelds, I.M., Villalón, C.M., Saxena, P.R., Bogers, A.J.J.C. & MaassenVanDenBrink, A. Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery. Naunyn-Schmiedeberg's Arch. Pharmacol., 374, 163-175, 2006. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. ).
  • Gupta, S., Villalón, C.M., Mehrotra, S., De Vries, R., Garrelds, I.M., Saxena, P.R. & MaassenVanDenBrink, A. Female sex hormones and rat dural vasodilatation to CGRP, periarterial electrical stimulation and capsaicin. Headache, 47, 225-235, 2007. (2016 JCR Impact Factor: 2.961).
  • Gupta, S., Mehrotra, S., Villalón, C.M., Perusquía, M., Saxena, P.R. & MaassenVanDenBrink, A. Potential role of female sex hormones in the pathophysiology of migraine. Pharmacology & Therapeutics, 113, 321-340, 2007. (2016 JCR Impact Factor: 11.000).
  • Mehrotra, S., Gupta, S., Villalón, C.M., Boomsma, F., Saxena, P.R. & MaassenVanDenBrink, A. Rat carotid artery responses to a‑adrenergic receptor agonists and 5‑HT after ovariectomy and hormone replacement. Headache, 47, 236‑246, 2007. (2016 JCR Impact Factor: 2.961).

  • Gupta, S., Lozano‑Cuenca, J., Villalón, C.M., de Vries, R., Garrelds, I.M., Avesta, C.J., van Katz, J.P., Saxena, P.R. & MaassenVanDenBrink, A. Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries. Naunyn‑Schmiedeberg’s Arch. Pharmacol., 375, 29‑38, 2007. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. ).
  • Mehrotra, S., Gupta, S., Centurión, D.,Villalón, C.M., Saxena, P.R. & MaassenVanDen Brink, A. A61603-induced contractions of the porcine isolated meningeal artery are mediated by a1 and a2-adrenoceptors. Basic Clin. & Toxicol., 100, 279-285, 2007. (2016 JCR Impact Factor: 3.097).
  • Görnemann, T., von Wenckstern, H., Kleuser, B., Villalón, C.M., Centurión, D., Jähnichen, S. & Pertz, H.H. Characterization of the postjunctional alpha(2C)-adrenoceptor mediating vasoconstriction to UK14304 in porcine pulmonary veins. Brit. J. Pharmacol., 151, 186-194, 2007. (2016 JCR Impact Factor: 5.491).
  • Perusquía, M. Navarrete, E., González, L. & Villalón, C.M. The modulatory role of androgens and progestins in the induction of vasorelaxation in human umbilical artery. Life Sci., 81, 993-1002, 2007. (2016 JCR Impact Factor: 2.685).

  • Villalón, C.M. & Centurión, D. Cardiovascular responses produced by 5-hydroxytryptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn‑Schmiedeberg’s Arch. Pharmacol., 376, 45-63, 2007. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. ).
  • Villalón, C.M., Albarrán-Juárez, J.A., Lozano-Cuenca, J., Pertz, H.H., Görnemann, T. & Centurión, D. Pharmacological profile of the clonidine‑induced inhibition of vasodepressor sensory outflow in pithed rats: correlation with a2A/2C Brit. J. Pharmacol., 154, 51-59, 2008. (2016 JCR Impact Factor: 5.491).

  • Mehrotra, S., Gupta, , Chan, K.Y., Villalón, C.M. Centurión, D., Saxena, P.R. & Maassen Van Den Brink, A. Current and prospective pharmacological targets in relation to antimigraine action. Naunyn‑Schmiedeberg’s Arch. Pharmacol., 378, 371-394, 2008. (2016 JCR Impact Factor: 2.558; aparece como N-S Arch. Pharmacol.).
  • Ramage, A.G. & Villalón, C.M. 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol. Sci., 29, 472-481, 2008. (2016 JCR Impact Factor: 12.797).
  • Lozano-Cuenca, J., González-Hernández, A., Muñoz-Islas, E., Sánchez-López, A., Centurión, D., Cobos-Puc, L.E. & Villalón, C.M. Pharmacological profile of inhibition produced by dihydroergotamine and methysergide on the cardioaccelerator sympathetic outflow in pithed rats. J. Pharmacol., 612, 80-86, 2009. (2016 JCR Impact Factor: 2.896).
  • Görnemann, T., Villalón, C.M., Centurión, D. & Pertz, H.H. Phenylephrine contracts porcine pulmonary veins via α1B-, α1D- and α2-adrenoceptors. Eur. J. Pharmacol., 613, 86‑92, 2009. (2016 JCR Impact Factor: 2.896).
  • Muñoz-Islas, E., Lozano-Cuenca, J., González-Hernández, A., Ramírez-Rosas, M.B., Sánchez‑López, A., Centurión, D., MaassenVanDenBrink, A. & Villalón, C.M. Spinal sumatriptan inhibits capsaicin‑induced canine external carotid vasodilatation via 5‑HT1B rather than 5-HT1D Eur. J. Pharmacol., 615, 133-138, 2009. (2016 JCR Impact Factor: 2.896).
  • Cobos-Puc, L.E., Villalón, C.M., Ramírez-Rosas, M.B., Sánchez-López, A., Lozano-Cuenca, J., Gómez-Díaz, B., MaassenVanDenBrink, A. & Centurión, D. Pharmacological characterization of the inhibition to moxonidine and agmatine on the cardioaccelerator sympathetic outflow in pithed rats. Eur. J. Pharmacol., 616, 175-182, 2009. (2016 JCR Impact Factor: 2.896).

  • Villalón, C.M. & Olesen, J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacology & Therapeutics, 124, 309-323, 2009. (2016 JCR Impact Factor: 11.000).
  • Chan, K.Y., Gupta, S., de Vries, R., Danser, A.H.J., Villalón, C.M., Muñoz-Islas, E. & MaassenVanDenBrink, A. Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model. Brit. J. Pharmacol., 160, 1316–1325, 2010. (2016 JCR Impact Factor: 5.491).
  • Chan, K.Y., Baun, M., de Vries, R., van den Bogaerdt, A.J., Dirven, C.M.F., Danser, A.H.J., Jansen-Olesen, I., Olesen, J., Villalón, C.M., MaassenVanDenBrink, A. & Gupta, S. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia, 31, 181-189, 2011. (2016 JCR Impact Factor: 6.052).

  • Labruijere, S., van Houten, E.L.A.F., de Vries, R., Musterd-Bagghoe, U.M., Garrelds, I.M., Kramer, P., Danser, A.H.J., Villalón, C.M., Visser, J.A. & MaassenVanDenBrink, A. Analysis of the vascular responses in a murine model of polycystic ovary syndrome. Endocrinology, 218, 205-213, 2013. (2016 JCR Impact Factor: 4.498).
  • Ramírez-Rosas, M.B., Labruijere, S., Villalón, C.M. & MaassenVanDenBrink, A. Activation of 5‑hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Expert Op. Pharmacother., 14, 1599-1610, 2013. (2016 JCR Impact Factor: 3.543).
  • Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalón C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M. The Concise Guide to PHARMACOLOGY 2013/14: overview. Brit. J. Pharmacol., 170, 1449-1458, 2013. (2016 JCR Impact Factor: 5.491).
  •  
  • Peatfield, R. & Villalón, C.M. Headache after exposure to 'date-rape' drugs. Springerplus, 2(1), 39, 2013.

  • Cuesta, C., García-Pedraza, J.Á., García, M., Villalón, C.M & Morán, A. Role of 5-HT7 receptors in the inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats. Vascular Pharmacol., 63, 4-12, 2014. (2016 JCR Impact Factor: 2.500).

  • Marichal-Cancino, B.A., Altamirano-Espinoza, A.H., Manrique-Maldonado, G., Maassenvandenbrink, A. & Villalón, C.M. Role of pre-junctional CB1 , but not CB2 , TRPV1 or GPR55 receptors in anandamide-induced inhibition of the vasodepressor sensory cgrpergic outflow in pithed rats. Basic Clin. Pharmacol. Toxicol., 114, 240–247, 2014. (2016 JCR Impact Factor: 3.097).
  • Manrique-Maldonado, G., González-Hernández, A., Altamirano-Espinoza, A.H., Marichal-Cancino, B.A., Ruiz-Salinas, I. & Villalón, C.M. The role of pre-junctional D2 -like receptors mediating quinpirole-induced inhibition of the vasodepressor sensory CGRPergic out-flow in pithed rats. Basic Clin. Pharmacol. Toxicol., 114, 174-180, 2014. (2016 JCR Impact Factor: 3.097).
  • Altamirano-Espinoza, A.H., Manrique-Maldonado, G., Marichal-Cancino, B.A. & Villalón, C.M. Specific role of α2A - and α2B -, but not α2C -, adrenoceptor subtypes in the inhibition of the vasopressor sympathetic out-flow in diabetic pithed rats. Basic Clin. Pharmacol. Toxicol., 117, 31-38, 2015. (2016 JCR Impact Factor: 3.097).

  • Pinacho-García M., Marichal-Cancino, B.A. & Villalón, C.M. Further evidence for the role of histamine H3, but no H1, H2 or H4, receptors in immepip-induced inhibition of the rat cardiaccelator sympathetic outflow. Eur. J. Pharmacol., 773, 85-92, 2016. (2016 JCR Impact Factor: 2.896).

  • Ruiz-Salinas, I., Rocha, L., Marichal-Cancino, B.A. & Villalón, C.M. Cardiovascular alterations during the interictal period in awake and pithed amygdala-kindled rats. Basic Clin. Pharmacol. Toxicol., 119, 165–172, 2016. (2016 JCR Impact Factor: 3.097).
  • MaassenVanDenBrink, A., Meijer, J., Villalón, C.M. & Ferrari M.D. Wiping Out CGRP: Potential Cardiovascular Risks. Trends Pharmacol. Sci., 37, 779-788, 2016. (2016 JCR Impact Factor: 12.797).

  • Villalón, C.M. & MaassenVanDenBrink, A. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments. Mini Rev. Med. Chem., 17, 928-938, 2017.

  • Rubio-Beltrán, E., Labastida-Ramírez, A., Hernández-Abreu, O., MaassenVanDenBrink, A., Villalón, C.M. Pharmacological analysis of the inhibition produced by moxonidine and agmatine on the vasodepressor sensory CGRPergic outflow in pithed rats. Eur. J. Pharmacol., 812, 97-103, 2017.
  • Rivera-Mancilla, E., Avilés-Rosas, V.H., Manrique-Maldonado, G., Altamirano-Espinoza, A.H., Villanueva-Castillo, B., MaassenVanDenBrink, A., Villalón, C.M. The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats. J. Headache Pain, 2017 Oct 11; 18(1):104. doi: 10.1186/s10194-017-0812-4.
  • González-Hernández, A., Marichal-Cancino, B.A., MaassenVanDenBrink, A., Villalón, C.M. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol., 14, 25-41, 2018.
  • Rubio-Beltrán, E., Labastida-Ramírez, A., Villalón, C.M., MaassenVanDenBrink, A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacology & Therapeutics 2018 Jan 17. pii: S0163-7258(18)30012-3. doi: 10.1016/j.pharmthera.2018.01.005. [Epub ahead of print] Review. PMID: 29352859.
  • García-Pedraza, J.Á., Hernández-Abreu, O., García, M., Morán, A., Villalón, C.M. Chronic 5-HT2 receptor blockade unmasks the role of 5-HT1F receptors in the inhibition of rat cardioaccelerator sympathetic outflow. Can. J. Physiol. Pharmacol. 2018 Apr;96(4):328-336. doi: 10.1139/cjpp-2017-0191.Epub 2017 Sep 8.
  • Labastida-Ramírez, A., Rubio-Beltrán, E., Villalón, C.M., MaassenVanDenBrink, A. Gender aspects of CGRP in migraine. Cephalalgia. 2019 Mar;39(3):435-444. doi: 10.1177/0333102417739584.Epub 2017 Oct 30.
  • Rivera-Mancilla, E., Al-Hassany, L., Villalón, C.M., MaassenVanDenBrink, A. Metabolic Aspects of Migraine: Association With Obesity and Diabetes Mellitus. Front Neurol. 2021 Jun 9;12:686398. doi: 10.3389/fneur.2021. Review.
  • Marichal-Cancino, B.A., González-Hernández, A., Guerrero-Alba, R., Medina-Santillán, R., Villalón, C.M. A critical review of the neurovascular nature of migraine and the main mechanisms of action of prophylactic antimigraine medications. Expert Rev Neurother. 2021 Sep;21(9):1035-1050. doi: 10.1080/14737175.2021.1968835
  • González-Hernández, A., Marichal-Cancino, B.A., Villalón, C.M. The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events. Expert Opin Drug Metab Toxicol. 2021 Oct;17(10):1223-1235. doi: 10.1080/17425255.2021.1982892. Review.
  • Eduardo Rivera-Mancilla , Belinda Villanueva-Castillo, Alain H. Altamirano-Espinoza, Guadalupe Manrique-Maldonado, Carlos M. Villalon. Prospective role of α2A/2B/2C-adrenoceptor subtypes in the modulation of cardioaccelerator sympathetic tone in an experimental model of diabetes. Eur J Pharmacol. 2022 Jul 4;929:175138. doi: 10.1016/j.ejphar.2022.175138. Online ahead of print. PMID: 35798051.
  • Eduardo Rivera-Mancilla, Alain H. Altamirano-Espinoza, Guadalupe Manrique-Maldonado, Belinda Villanueva-Castillo, Carlos M. Villalon. Streptozotocin-induced diabetes in rats modifies the role D2, D3 and D4 dopamine receptors play in cardiac sympathetic inhibition. Basic Clin Pharmacol Toxicol. 2022 Jul 14. doi: 10.1111/bcpt.13774. Online ahead of print. PMID: 35834260.
  • Eloísa Rubio-Beltrán, Rianne M. Schoon, Jeffrey van den Berg, Catharina C.M. Schuiling-Veninga, Birgit C.P. Koch, Carlos M. Villalón, Jorie Versmissen, A.H. Jan Danser, Anton H. van den Meiracker, Khatera Ibrahimi, Antoinette MaassenVanDenBrink. Trigeminovascular effects of propranolol in men and women, role for sex steroids. Ann Clin Transl Neurol. 2022 Sep;9(9):1405-1416. doi: 10.1002/acn3.51640.
  •  
  • Alejandro D. Miguel-Martínez, Juan Linares-Bedolla, Belinda Villanueva-Castillo, Kristian A. Haanes, Antoinette MaassenVanDenBrink, Carlos M. Villalón. Pharmacological Profile of the Purinergic P2Y Receptors That Modulate, in Response to ADPβS, the Vasodepressor Sensory CGRPergic Outflow in Pithed Rats. Pharmaceuticals. 2023 Mar 22;16(3):475. doi: 10.3390/ph16030475.

3.2. Chapters Published in International Books by Prestigious Publishers

Villalón, C.M., Den Boer, M.O., Heiligers, J.P.C. & Saxena, P.R.: The 5‑HT4 receptor mediating tachycardia in the pig. In: Serotonin: Molecular Biology, Receptors and Function. Editors:Fozard,J.R. & Saxena, P.R., Birkhäuser, Basel, 1991. pp. 253‑263.

Van Heuven, D., Villalón, C.M., Den Boer, M.O. & Saxena, P.R. 5‑HT1‑like receptors unrelated to the known binding sites? In: Serotonin: Molecular Biology, Receptors and Function. Editors:Fozard,J.R. & Saxena, P.R., Birkhäuser, Basel, 1991, pp. 192‑200.

Villalón, C.M. & Saxena, P.R. Classification of 5‑hydroxytryptamine receptors., In:Headache and Migraine. Editors: Hogenhuis, L.A.H. & Steiner, T.J., Bunge, Utrecht, 1992, pp. 31‑49.

Tadipatri, S., Van Heuven, D., Villalón, C.M., Bax, W.A. & Saxena, P.R. Effects of antimigraine drugs ergotamine and sumatriptan on the rabbit isolated blood vessels. In: 5‑HTMechanisms in Primary Headaches. Editors: Olesen, J. & Saxena, P.R., Raven Press, NewYork, 1992, pp. 323‑329.

Saxena, P.R., Ferrari, M., De Vries, P. & Villalón, C.M. Pharmacological overview of new 5‑HT1D receptor agonists in development for the acute treatment of migraine. In: Headache Treatment: Trial Methodology and New Drugs (Volume6), Editors: Olesen, J. & Tfelt‑Hansen, P., RavenPress, NewYork, 1997, pp.229‑241.

De Vries, P., Willems, E.W., Heiligers, J.P.C., Villalón, C.M. & Saxena, P.R. Constriction of porcine carotid anastomoses as indicator of antimigraine activity: the role of 5‑HT1B/1D receptors as well as unidentified receptors. In: Migraine & Headache Pathophysiology, Editor: Edvinsson, L., Martin Dunitz Publishers, London, 1999, pp.119-131.

Arulmani, U., Villalón, C.M. & Saxena, P.R. Effects of BIBN4096BS on capsaicin-induced haemodynamic changes in a porcine experimental model for migraine. In: Headache and Migraine, Editors: Couturier, E., Sorbi, M.J. & Verspui, E.C.B., A-D Druk B.V., Utrecht, 2004, pp. 85-105.

Mehrotra, S., Gupta, S., Villalón, C.M., Centurión, D., Saxena, P.R. & MaassenVanDenBrink, A. Current and potential pharmacological targets for migraine therapy. In: Headache and Migraine 10, Editors: Couturier, E., Sorbi, M.J. & van Bokhorst, J., Anglo Dutch Migraine Association., A‑D Druk B.V., Amsterdam, 2008, pp.59‑82.

Gupta, S., Mehrotra, S., Villalón, C.M., De Vries, R., Garrelds, I.M., Saxena, P.R. & MaassenVanDenBrink, A. Potential role of sex steroids in migraine pathophysiology. In: Headache and Migraine 10, Editors: Couturier, E., Sorbi, M.J. & van Bokhorst, J., Anglo Dutch Migraine Association., A‑D Druk B.V., Amsterdam, 2008, pp. 83-103.

Centurión, D., Cobos-Puc, L.E., Ramírez-Rosas, M.B., Gómez-Díaz, B., Sánchez-López, A. & Villalón, C.M. Pithed rat model for searching vasoactive drugs and studying the modulation of the sympathetic and non-adrenergic non-cholinergic outflow. In: Models of Neuropharmacology, Editors: Rocha, L.L. & Granados-Soto, V., Transworld Research Network. Kerala, 2009, pp. 91-97.

Villalón, C.M., Lozano-Cuenca, J., Muñoz-Islas, E. González-Hernández, A., Sánchez-López, A. & Centurión, D. Experimental vascular models of migraine and their relevance in antimigraine therapy. In: Models of Neuropharmacology, Editors: Rocha, L.L. & Granados-Soto, V., Transworld Research Network. Kerala, 2009, pp. 213-227.

Edvinsson, L., MaassenVanDenBrink, A. & Villalón, C.M. Mechanisms of migraine and its treatment. In: Handbook of Headache: Practical Management (Editors: Paolo Martelletti & Timothy J. Steiner). Springer, 2011, pp. 239-254. ISBN 8847016991, 9788847016996

II.13 Villalón, C.M. The role of serotonin receptors in the control of cardiovascular function. In: The Serotonin System: History, Neuropharmacology, and Pathology. Eds. Tricklebank MD and Daly E. Academic Press (Elsevier Inc.), 2019, pp. 45-61. DOI: https://doi.org/10.1016/B978-0-12-813323-1.00014-1

3.3. Publications/ Works in Local (Mexican) Journals

Terrón, J.A., Ibarra, M., Ranzans, V., Hong, E. & Villalón, C.M. Propiedades antiadrenérgicas alfa de la espiroxatrina, un ligando de los receptores 5‑HT1A. Arch. Inst. Cardiol. Méx., 63, 289‑295, 1993.

Villalón, C.M., Terrón, J.A., Hong, E., & Saxena, P.R. Mecanismos involucrados en los efectos cardíacos de la 5‑HT. Arch. Inst. Cardiol. Méx., 63, 161‑165, 1993.

Villalón, C.M., Terrón, J.A., Hong, E., & Saxena, P.R. Efectos cardiovascularesdeagonistas y antagonistas de los receptores a la 5‑HT (ParteI). Arch. Inst. Cardiol. Méx., 63, 441‑447, 1993.

Villalón, C.M., Terrón, J.A., Hong, E., & Saxena, P.R. Efectos cardiovascularesdeagonistas y antagonistas de los receptores a la 5‑HT (ParteII). Arch. Inst. Cardiol. Méx., 63, 553‑561, 1993.

Villalón, C.M., Terrón, J.A., Ramírez‑San Juan, E. & Saxena, P.R. Interacciones entre el sistema renina‑angiotensina‑aldosterona y la neurotransmisión simpática. Arch. Inst. Cardiol. Méx., 65, 89‑94, 1995.

Terrón, J.A., Ramírez‑San Juan, E. & Villalón, C.M. Comparación de los efectos de la serotonina, 2‑(2‑aminoetil)‑quinolina (D‑1997) y sumatriptan sobre el flujo sanguíneo carotídeo externo del perro. Arch. Inst. Cardiol. Méx., 65, 13‑18, 1995.

Sánchez-López, A., Centurión. D, Lozano-Cuenca, J., Muñoz-Islas, E., Cobos-Puc, L.E. & Villalón, C.M. Receptores de la serotonina que inhiben el tono simpático vaso-presor en la rata descerebrada y desmedulada. Arch. Cardiol. Méx., 79 (Suppl 2), 83-94, 2009.

 

Further Reading
In this part, we encourage you to list the link of papers wrote by the character, or published reviews/articles about his/her academic contributions. Edit
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Carlos M. Villalón
Name: Carlos M. Villalón
Born: Nov 1959
Birth
Location: Mexico City, Mexico
Title: Scientist (Full Professor)
Affiliation: Department of Pharmacobiology, Cinvestav-IPN (South Campus), 14330 Mexico City, Mexico
Honor: Professor Emeritus
Upload a video for this entry
Information
Subjects: Pharmacology & Pharmacy
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Carlos M. Villalón
View Times: 713
Entry Collection: Hypertension and Cardiovascular Diseases
Revisions: 5 times (View History)
Update Date: 18 Jul 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback